Navigation Links
YM BioSciences raises US$3.2 million in support of JAK 1/2 program
Date:6/3/2010

-Proceeds to support acceleration of CYT387 Phase II myelofibrosis study-

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010. Listing of the common shares sold has been approved by the NYSE Amex and conditionally approved by the Toronto Stock Exchange (TSX) subject to the Company fulfilling all the requirements of the TSX. The investment was made by a leading international health-care-specific investment fund management company recognizing the increased demands on YM's cash resources from the recently announced expansion by the Company into the earlier-than-planned Phase II component of its trial at Mayo Clinic with CYT 387 in myelofibrosis.

"The recent decision by the company to accelerate the current Phase I/II clinical trial of CYT387 in myelofibrosis through an earlier-than-planned initiation of the Phase II component supports our belief that CYT387 has excellent potential for clinical success," said David Allan, Chairman and CEO of YM BioSciences. "We anticipate that headline safety and tolerability data from the Phase I arm of this study will be available in the next quarter with preliminary Phase II data expected to be submitted for presentation at the American Society of Hematology conference late in 2010. The company is also exploring opportunities for significant further expansion of the program, in light of the favourable findings to date."

The previously announced ex
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
2. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
5. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
6. YM BioSciences third quarter 2010 operational and financial results
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
9. YM BioSciences announces controlled equity offering
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
11. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Human Albumin Industry Report 2014" report ... Albumin Industry Report 2014 is a professional and in-depth ... albumin industry. The report provides a basic ... industry chain structure. The human albumin market analysis is ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... Woburn, MA (PRWEB) September 18, 2014 ... Single Molecule Sequencing (tSMS™) technology, announced today the ... round of investment, led by Genomic Diagnostic Technologies, ... scientific and diagnostic applications. , Founded in March ... Scientist and Bioinformatics Analyst at Helicos BioSciences, SeqLL ...
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Using solar energy to turn raw materials into ingredients for every day life 2
... University of Wisconsin Medical Foundation is initiating ... Foundation's clinical data and to improve the reliability of ... QDX Platform V Integration Services from Quovadx, ... in Englewood, Colorado. , ,The Medical Foundations growth ...
... of single-molecule DNA analysis technology, announced Thursday it has commenced ... tumor, known as oligodendroglioma. OpGen, based in Madison, is working ... of genetics and chemistry at the University of Wisconsin-Madison and ... mapping, invented by Schwartz, will enable researchers to determine how ...
... weeks ago, I referred to offshore outsourcing as an ... an issue de lannee (an election year at that ... questions about the economic future of the U.S. Prominent ... the contenders for the Democratic presidential nomination to the ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2The Great Offshore Outsourcing Debate 2
(Date:9/18/2014)... are the ideal animal in which to study the ... ocean into tens of thousands of freshwater streams and ... to adapt to the new environment. , Breeding studies ... turned up one of the genes that controls tooth ... gene,s regulation in a freshwater population is associated with ...
(Date:9/17/2014)... creation of the Santa Ana Wildfire Threat Index ... of the powerful, hot, dry Santa Ana wind, which ... was introduced Sept. 17 by the U.S. Forest Service, ... Electric. , The index includes four classification levels ranging ... help fire agencies and other emergency responders, the media ...
(Date:9/17/2014)... USA -- "Nature has developed, very cleverly, some lessons ... in optical design," said Joseph Shaw, director of the ... explore surfaces and structures at the nanoscale, we,ll discover ... San Diego in August during a conference called "The ... and Rongguang Liang of the University of Arizona College ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... LA Research led by Lauren Cole, a public ... of Public Health and Director of the Epidemiology Program ... the incidence of head and neck cancer has risen ... with the greatest increase among middle-aged white men. At ...
... gene called XRCC2 cause increased breast cancer risk, according to ... Human Genetics . The study looked at families that have ... in the currently known breast cancer susceptibility genes. Sean ... professor in the Department of Oncological Sciences at the University ...
... such as the Iberian lynx, are under an increasingly serious ... that can even survive in extremely arid environments. A study ... to adapt according to climate. The life cycle of ... patterns of people and goods. These parasites and the pathogens ...
Cached Biology News:LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men 2A new breast cancer susceptibility gene 2Ticks can adapt to the Spain's climatic diversity 2
Human PDGF, CF...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: